standard test for what remains a clinical dilemma, distinguishing AA from hMDS. This is in part, we believe, because CD34 numbers, although statistically different between the disease groups, showed considerable overlap in several studies. Rather than attempting to 'reinvent the wheel,' we believe that our results build upon past studies by providing clinical outcomes that improve the ability to classify patients with either disease state. When doing this, we find no overlap in marrow CD34 numbers between AA and hMDS, and thus believe quantifying marrow CD34 numbers should be further tested as a standard approach for separating the two disorders. Furthermore, these findings also suggest that patients with normal cytogenetics and low CD34 þ percentages are at a low risk of disease progression and may be managed in a conservative manner in the absence of life-threatening cytopenias. 
I did appreciate the reply letter from Dr Matsui et al., 1 which I believe clarifies most of the issues I had raised in reference to their recent paper. 2 However, their reply, which refers to 'a potential confounding factor in their (our) analysis 3 may have come from reliance on the FAB guidelines to accurately diagnose patients', is still somewhat misleading. Although the presence of a cytogenetic abnormality is useful in confirming a suspected diagnosis of myelodysplastic syndrome (MDS), its present is not mandated by either FAB or WHO 2001 guidelines. The diagnostic criteria for MDS in both classifications largely overlap. Therefore, the assumption that we might have 'misclassified' cases because of the use of FAB (the only system available in 1996) is incorrect.
I completely agree with Dr Matsui et al. 1 that the enumeration of bone marrow CD34 positive cells should be further tested, possibly in a randomized prospective way, in order to conclusively confirm its validity for separating the two disorders. The fact that the 'CD34 approach' has not become standard of practice up to now, I suspect, it is also due to the usual interlaboratory variability which plagues immunohistochemistry laboratories in general. As this is not likely to change in the near future, the best approach to this difficult differential diagnosis remains, in my judgment, a comprehensive one inclusive of morphology, immunohistology, flow cytometry and cytogenetics. Marrow cytogenetics still maintains its major prognostic role in this group of hypoplastic marrow disorders. Sphingolipids and their metabolites recently appeared as a potent class of regulators of cell proliferation, survival as well as apoptosis. 1 The ceramide/S1P rheostat has been proposed as the model to determine the cell's fate. 2 This rheostat is being increasingly recognized as a critical element in tumor cell proliferation and chemotherapy. Sphingomyelinase is responsible for the first step of the sphingomyelin-catabolic pathway and produces ceramide, which figures mostly as the proapoptic factor in response to various reagents including anti-cancer drug or radiation. On the contrary, sphingosine kinase (SPHK) is the enzyme that produces sphingosine 1-phosphate (S1P) from sphingosine. S1P binds to five G-protein coupled receptors called S1P receptors. S1P promotes cell survival or motion as the first or second cellular messenger in response to various agonists. Therefore, enzymes in this pathway provide potential targets for new anti-cancer drugs.
Interestingly, overexpression of SPHK1 is thought to be oncogenic, and renders transfected cells chemoresistant.
2
SPHK1 mRNA was significantly higher in various cancer tissues than in their normal counterparts. 3 In prostate cancer cell lines, we reported the inverse relationship between SPHK1 level and anti-cancer drug sensitivity. 4 The quantity of each cellular sphingolipid metabolite was thought to be determined by the complex balance between each metabolic enzyme activity and substrate. However, no analysis of gene expression of sphingolipid metabolizing enzymes including SPHK1 of acute leukemia or related diseases has been reported.
In the present study, we performed quantitative RT-PCR assay to measure the mRNA levels of nine major enzymes involved in the sphingolipid metabolic pathway including sphingosine kinase 1 (SPHK1), sphingosine kinase 2 (SPHK2), acid sphingomyelinase (ASMase), neutral sphingomyelinase 2 (NSMase2), acid ceramidase (ACDase), sphingosine 1-phosphate lyase (SPL), sphingosine 1-phosphate phosphatase 1 (SPP1), glucosyl ceramide synthase (GlcCer Syn), sphingomyelin synthase 1 (SM Syn). Multidrug-resistant gene (MDR) and BCL2 were also measured to examine the chemoresistance gene expression in the current samples.
Quantitative PCR was performed with Power SYBR Green master mix (Applied Biosystems, Foster City, CA, USA) in duplicate using primer sets described in Table 1 , and ABI PRISM 7000 sequence detection systems (Applied Biosystems) were used for the measurement. ABL gene expression was measured as the internal control with Taqman probe as shown in Table 1 according to the recommendation by Beillard et al. 5 The specificity of PCR product was confirmed in the preliminary experiments using cell lines. Standard curve was created using cDNA fragment of each enzyme produced by the PCR method and then inserted into the cloning vector. The relative gene expression level was calculated as the ratio of each gene expression/ABL gene expression.
After obtaining informed consent, bone marrow cells were collected from 19 patients with acute leukemia and 60 patients with myelodysplastic syndromes (MDS) (28 RA (refractory anemia), 21 RAEB (refractory anemia with excessive blast) and 11 RAEB-t (RAEB in transformation) according to FAB classification) mostly at their initial diagnosis or before any treatment. For the normal control, bone marrow samples for the disease staging were used from 11 patients with non-Hodgkin's lymphoma without bone marrow invasion. Mononuclear cells were collected and RNA was extracted. The first strand cDNA was prepared using the Super Script First-Strand System (Invitrogen). CML-BC and Ph 1 þ ALL samples were omitted because the ABL gene was used as the internal control of RT-PCR assay. Patient characteristics are provided as the Supplementary Data. Figure 1 shows the message levels of sphingolipid metabolic enzymes as well as BCL2 and MDR. We mainly focused on the statistical difference between AL and normal control by using one-way factorial analysis of variance and multiple comparison test (Bonferroni/Dunn's method). Statistical analysis was performed using Microsoft Excel software and Stat view version 5 (SAS Institute Inc., Cary, NC, USA). We used RNA from total mononuclear cells of bone marrow aspirates instead of purified hematopoietic stem cells or blast cells. Therefore, the heterogeneity of bone marrow component might have affected our results.
Among enzymes examined, AL also showed noticeable increases of SPHK1 message as compared to normal population. Some AL showed more than 2 log order higher SPHK1 gene expression as compared to the normal control. SPHK2 did not show significant differences between groups analyzed. It is also of note that SPHK1 expression of RAEB-t is also significantly higher than normal, although we could not see significant differences in SPHK1 gene expression between RAEB and normal control. There was no correlation between the SPHK1 gene expression level and abnormal karyotypes with poor prognosis such as seven monosomy or complex abnormality (data not shown), suggesting that SPHK1 gene expression is independent from karyotype abnormality. Although we did not make a sequential analysis of the same MDS patient, SPHK1 might be a candidate of the surrogate marker of AL and MDS, because its expression gradually increased during the progression of MDS and high in AL.
Okazaki's group 6 reported the correlation between chemoresistance and the increase of glucosylceramide synthase and spingomyelin synthase in leukemia cell lines and a small clinical sample. The increase of these enzyme activities might decrease the cellular ceramide level. However, the significance of these findings has not been repeated by others. In our analysis, the message levels of these genes did not show any significant difference between AL and normal control. ASMase, ACDase and SPL were not different between AL and normal control.
Interestingly, NSMase2 was decreased in AL, RAEB and RA samples as compared to normal control. Among SMases, NSMase2 has been cloned recently and was reported to play as a growth suppressor linking confluence to the G0/G1 cell cycle checkpoint. 7 The decrease of NSMase2 in AL is an unexpected and novel finding. Considering the sphingolipid rheostat model, either the increase of SPHK1 or the decrease of NSMase2 gene expression results in the decrease of ceramide/ S1P ratio in leukemia blast cells, which might stimulate cell proliferation or survival. Although the regulatory mechanism of ASMase gene expression was reported in cell lines, the transcriptional regulation of NSMase2 has not been clarified yet, and is an interesting topic for future analysis. Statistical significance was also observed in SPP1 only between AL and normal control but not between MDS and normal control. As for SPL and SPP1, which convert S1P to phosphoethanolamine and palmitaldehyde, or sphingosine, respectively, we only observed the increase in SPP1 message but not SPL. The increase of SPP1 expression is also thought to modulate the ceramide/S1P rheostat, however, the significance of this finding remains to be determined.
As to other well-known chemoresistance genes, MDR showed no significant difference between AL and normal control. On the contrary, statistical significance was observed in BCL2 between AL and normal, but not between MDS and normal control. We analyzed the relationship between SPHK1 and MDR or SPHK1 and BCL2 gene expression. In AL, there was no relationship between SPHK1 gene expression level and two well-recognized genes of chemoresistance, MDR and BCL2, of the same sample (precise data not shown). This could suggest that SPHK1 is not always located downstream of BCL2 in AL.
Furthermore, it was also revealed that there are no correlationships between SPHK1 and NSMase2, between SPHK1 and SPP1 gene expression, or between SPHK1 and SPHK2 gene expression. Apoptosis induction can be suitable for the treatment of diseases such as malignant tumors. The trials of novel inhibitors of SPHK1 are based on the hypothesis that the modification of ceramide/S1P rheostat induces apoptosis of malignant tumor cells and enhances chemosensitivity. Actually, a synthetic compound with SPHK inhibitor activity can induce apoptosis in tumor cells even with multidrug resistance. 3 As we 4 recently reported that SPHK1 activity is a chemotherapy sensor in prostate cancer cells, and overexpression of SPHK1 has been reported in solid tumors, 3 it is of interest to know whether this observation can be applied to hematological malignancies, especially acute leukemia and MDS. Such data are important because the relapse after intensive chemotherapy is still an unsolved problem in leukemia treatment, and new remedies are urgently required. Our data showed AL or RAEB-t cases with much higher SPHK1 gene expression compared to normal. Therefore, it is suggested that the development of new SPHK1 inhibitor is also beneficial for AL patients whose SPHK1 gene expression (and probably SPHK enzyme activity) is enhanced. 
Letters to the Editor
Bonhoure et al. 8 reported that sustained SPHK1 overexpresion can render HL60 cells chemoresistant by decreasing the cellular ceramide level and that a novel SPHK1 inhibitor, F-12509a, could recover chemosensitivity. Considering the molecular target of chemotherapy, enzyme inhibitors are more practical than agents for enzyme activation (NSMase2 in our case). Inhibitor of SPHK1 is almost at the stage of clinical investigation. In the present study, we could analyze only one time point of patients (mostly at their first diagnosis before chemotherapy) and could not measure enzyme activities due to the paucity of samples. The measurement of SPHK1 gene expression and/or SPHK enzyme activity of each patient might be necessary to assess the efficacy of enzyme inhibitors in future clinical settings. Sequential analysis of the same patients will also add further information.
The localization and activation of enzymes are also important factors to determine the final cellular ceramide/S1P rheostat. SPHK1 was reportedly activated by phosphorylation by agonists and translocated to membranes. 2 Therefore, further analysis of enzyme activation is necessary to conclude firmly that sphingolipid metabolizing enzymes such as SPHK1 are a novel and promising molecular target for acute leukemia chemotherapy.
Taken together, this is, to our knowledge, the first report of a gene expression profile of major sphingolipid metabolizing enzymes of AL and MDS using quantitative RT-PCR, It documents the increase of SPHK1 gene expression in AL and RAEB-t and the decrease of NSMase2 gene expression in AL and RAEB, suggesting that sphingolipid metabolizing enzymes such as SPHK1 could be a novel target for the chemotherapy of AL.
